CLENE REPORTS SIGNIFICANTLY IMPROVED SURVIVAL BENEFIT OF 19.3 MONTHS AND SIGNIFICANTLY DELAYED CLINICAL WORSENING IN RESCUE-ALS OPEN-LABEL EXTENSION TWO YEAR FOLLOW-UP
19.3 month significant survival difference for CNM-Au8® treated participants versus placebo 52% significant decreased risk of ALS clinical worsening events Over 475 years of CNM-Au8 treatment exposure without any identified safety signals SALT LAKE CITY, Aug. 29, 2023 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) through its wholly owned subsidiary Clene Nanomedicine Inc., today announced […]